A class action lawsuit has been filed against Regenxbio Inc. in the United States District Court for the District of Maryland, alleging that the company provided false and misleading statements to investors regarding the safety and efficacy of its gene therapy candidate, RGX-111. The complaint claims that Regenxbio made positive assertions about RGX-111’s prospects while concealing adverse facts from investors. The situation escalated after the company announced on January 28, 2026, that the FDA had placed a clinical hold on RGX-111 following the discovery of a CNS tumor in a participant in the Phase I/II study. This announcement led to a significant decline in the company’s stock price. Investors who purchased Regenxbio securities between February 9, 2022, and January 27, 2026, have until April 14, 2026, to seek appointment as lead plaintiff in the case.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602131752PRIMZONEFULLFEED9654849) on February 13, 2026, and is solely responsible for the information contained therein.